Cost of start-up activities to implement a community-level opioid overdose reduction intervention in the HEALing Communities Study.
Community engagement
Cost analysis
Intervention implementation
Opioid use disorder
Start-up cost
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
02
04
2023
accepted:
18
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
2
4
2024
Statut:
epublish
Résumé
Communities That HEAL (CTH) is a novel, data-driven community-engaged intervention designed to reduce opioid overdose deaths by increasing community engagement, adoption of an integrated set of evidence-based practices, and delivering a communications campaign across healthcare, behavioral-health, criminal-legal, and other community-based settings. The implementation of such a complex initiative requires up-front investments of time and other expenditures (i.e., start-up costs). Despite the importance of these start-up costs in investment decisions to stakeholders, they are typically excluded from cost-effectiveness analyses. The objective of this study is to report a detailed analysis of CTH start-up costs pre-intervention implementation and to describe the relevance of these data for stakeholders to determine implementation feasibility. This study is guided by the community perspective, reflecting the investments that a real-world community would need to incur to implement the CTH intervention. We adopted an activity-based costing approach, in which resources related to hiring, training, purchasing, and community dashboard creation were identified through macro- and micro-costing techniques from 34 communities with high rates of fatal opioid overdoses, across four states-Kentucky, Massachusetts, New York, and Ohio. Resources were identified and assigned a unit cost using administrative and semi-structured-interview data. All cost estimates were reported in 2019 dollars. State-level average and median start-up cost (representing 8-10 communities per state) were $268,657 and $175,683, respectively. Hiring and training represented 40%, equipment and infrastructure costs represented 24%, and dashboard creation represented 36% of the total average start-up cost. Comparatively, hiring and training represented 49%, purchasing costs represented 18%, and dashboard creation represented 34% of the total median start-up cost. We identified three distinct CTH hiring models that affected start-up costs: hospital-academic (Massachusetts), university-academic (Kentucky and Ohio), and community-leveraged (New York). Hiring, training, and purchasing start-up costs were lowest in New York due to existing local infrastructure. Community-based implementation similar to the New York model may have lower start-up costs due to leveraging of existing infrastructure, relationships, and support from local health departments.
Sections du résumé
BACKGROUND
BACKGROUND
Communities That HEAL (CTH) is a novel, data-driven community-engaged intervention designed to reduce opioid overdose deaths by increasing community engagement, adoption of an integrated set of evidence-based practices, and delivering a communications campaign across healthcare, behavioral-health, criminal-legal, and other community-based settings. The implementation of such a complex initiative requires up-front investments of time and other expenditures (i.e., start-up costs). Despite the importance of these start-up costs in investment decisions to stakeholders, they are typically excluded from cost-effectiveness analyses. The objective of this study is to report a detailed analysis of CTH start-up costs pre-intervention implementation and to describe the relevance of these data for stakeholders to determine implementation feasibility.
METHODS
METHODS
This study is guided by the community perspective, reflecting the investments that a real-world community would need to incur to implement the CTH intervention. We adopted an activity-based costing approach, in which resources related to hiring, training, purchasing, and community dashboard creation were identified through macro- and micro-costing techniques from 34 communities with high rates of fatal opioid overdoses, across four states-Kentucky, Massachusetts, New York, and Ohio. Resources were identified and assigned a unit cost using administrative and semi-structured-interview data. All cost estimates were reported in 2019 dollars.
RESULTS
RESULTS
State-level average and median start-up cost (representing 8-10 communities per state) were $268,657 and $175,683, respectively. Hiring and training represented 40%, equipment and infrastructure costs represented 24%, and dashboard creation represented 36% of the total average start-up cost. Comparatively, hiring and training represented 49%, purchasing costs represented 18%, and dashboard creation represented 34% of the total median start-up cost.
CONCLUSION
CONCLUSIONS
We identified three distinct CTH hiring models that affected start-up costs: hospital-academic (Massachusetts), university-academic (Kentucky and Ohio), and community-leveraged (New York). Hiring, training, and purchasing start-up costs were lowest in New York due to existing local infrastructure. Community-based implementation similar to the New York model may have lower start-up costs due to leveraging of existing infrastructure, relationships, and support from local health departments.
Identifiants
pubmed: 38566249
doi: 10.1186/s13722-024-00454-w
pii: 10.1186/s13722-024-00454-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Subventions
Organisme : SAMHSA HHS
ID : UM1DA049394
Pays : United States
Organisme : SAMHSA HHS
ID : UM1DA049406
Pays : United States
Organisme : SAMHSA HHS
ID : UM1DA049412
Pays : United States
Organisme : SAMHSA HHS
ID : UM1DA049415
Pays : United States
Organisme : SAMHSA HHS
ID : UM1DA049417
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Aldridge AP, Barbosa C, Barocas JA, Bush JL, Chhatwal J, Harlow KJ, Hyder A, Linas BP, McCollister KE, Morgan JR, Murphy SM, Savitzky C, Schackman BR, Seiber EE, Starbird EL, Villani J, Zarkin GA. Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug Alcohol Depend. 2020;217(October):108336. https://doi.org/10.1016/j.drugalcdep.2020.108336 .
doi: 10.1016/j.drugalcdep.2020.108336
pubmed: 33152672
pmcid: 7532345
Behrends CN, Gutkind S, Winkelstein E, Wright M, Dolatshahi J, Welch A, Paone D, Kunins HV, Schackman BR. Costs of opioid overdose education and naloxone distribution in New York City. Subst Abuse. 2022;43(1):692–8. https://doi.org/10.1080/08897077.2021.1986877 .
doi: 10.1080/08897077.2021.1986877
Braithwaite V, Nolan S. Hospital-based addiction medicine healthcare providers: high demand, short supply. J Addict Med. 2019;13(4):251–2. https://doi.org/10.1097/ADM.0000000000000488 .
doi: 10.1097/ADM.0000000000000488
pubmed: 30633046
pmcid: 6750948
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani RWMA, Potee RA, Ryan D, Murphy SM, Walley AY, Linas BP. Estimated costs and outcomes associated with use and nonuse of medications for opioid use disorder during incarceration and at release in Massachusetts. JAMA Netw Open. 2023;6(4): e237036. https://doi.org/10.1001/jamanetworkopen.2023.7036 .
doi: 10.1001/jamanetworkopen.2023.7036
pubmed: 37058306
pmcid: 10105308
Claypool AL, DiGennaro C, Russell WA, Yildirim MF, Zhang AF, Reid Z, Stringfellow EJ, Bearnot B, Schackman BR, Humphreys K, Jalali MS. Cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids. JAMA Health Forum. 2023;4(5): e231080. https://doi.org/10.1001/jamahealthforum.2023.1080 .
doi: 10.1001/jamahealthforum.2023.1080
pubmed: 37204803
pmcid: 10199347
Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, Oliva EM, Goldhaber-Fiebert JD, Asch SM, Brandeau ML, Owens DK. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiat. 2021;78(7):767–77. https://doi.org/10.1001/jamapsychiatry.2021.0247 .
doi: 10.1001/jamapsychiatry.2021.0247
Garcia CC, Bounthavong M, Gordon AJ, Gustavson AM, Kenny ME, Miller W, Esmaeili A, Ackland PE, Clothier BA, Bangerter A, Noorbaloochi S, Harris AHS, Hagedorn HJ. Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder. Implement Sci Commun. 2023;4(1):91. https://doi.org/10.1186/s43058-023-00482-8 .
doi: 10.1186/s43058-023-00482-8
pubmed: 37563672
pmcid: 10413546
HEALing Communities Study Consortium, Walsh SL, El-bassel N, Jackson RD, Samet JH, Aggarwal M, Aldridge AP, Baker T, Barbosa C, Barocas JA, Battaglia TA, Beers D, Bernson D, Bowers-sword R, Bridden C, Brown JL, Bush HM, Bush JL, Button A, Chandler RK. The HEALing (Helping to end addiction long-term sm) communities study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335. https://doi.org/10.1016/j.drugalcdep.2020.108335 .
doi: 10.1016/j.drugalcdep.2020.108335
Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63. https://doi.org/10.2105/AJPH.2015.302664 .
doi: 10.2105/AJPH.2015.302664
pubmed: 26066931
pmcid: 4504312
Kavanaugh PR, McLean K. Motivations for diverted buprenorphine use in a multisite qualitative study. J Drug Issues. 2020;50(4):550–65. https://doi.org/10.1177/0022042620941796 .
doi: 10.1177/0022042620941796
Lefebvre RC, Chandler RK, Helme DW, Kerner R, Mann S, Stein MD, Reynolds J, Slater MD, Anakaraonye AR, Beard D, Burrus O, Frkovich J, Hedrick H, Lewis N, Rodgers E. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108338. https://doi.org/10.1016/j.drugalcdep.2020.108338 .
doi: 10.1016/j.drugalcdep.2020.108338
pubmed: 33152673
pmcid: 7534788
National Center for Health Statistics. U.S. Census Populations With Bridged Race Categories. 2022. https://www.cdc.gov/nchs/nvss/bridged_race.htm Accessed 2 Nov 2023.
National Center for O*NET Development. O*NET Online. 2022. https://www.onetonline.org/ . Accessed 1 Mar 2022.
Sprague Martinez L, Rapkin BD, Young A, Freisthler B, Glasgow LS, Hunt T, Salsberry PJ, Oga EA, Bennet-Fallin A, Plouck TJ, Drainoni ML, Freeman PR, Surratt H, Gulley J, Hamilton GA, Bowman P, Roeber CA, El-Bassel N, Battaglia T. Community engagement to implement evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217(2020):108326. https://doi.org/10.1016/j.drugalcdep.2020.108326 .
doi: 10.1016/j.drugalcdep.2020.108326
pubmed: 33059200
pmcid: 7537729
Onuoha EN, Leff JA, Schackman BR, McCollister KE, Polsky D, Murphy SM. Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value Health. 2021;24(7):1068–83. https://doi.org/10.1016/j.jval.2020.12.023 .
doi: 10.1016/j.jval.2020.12.023
pubmed: 34243831
pmcid: 8591614
U.S. Bureau of Labor Statistics. (2020). Employer Costs for Employee Compensation News Release. Economic News Release. 2020. https://www.bls.gov/news.release/archives/ecec_12172020.htm . Accessed 5 Apr 2021.
United States Census Bureau. Census Bureau Data. 2021. https://data.census.gov/ Accessed 2 Nov 2023.
Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M, Brown JL, Freeman PR, Nunes E, Beers D, Saitz R, Stambaugh L, Oga EA, Herron N, Baker T, Cook CD, Roberts MF, Alford DP, Starrels JL, Chandler RK. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108325. https://doi.org/10.1016/j.drugalcdep.2020.108325 .
doi: 10.1016/j.drugalcdep.2020.108325
pubmed: 33091842
pmcid: 7533113
Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–27. https://doi.org/10.1016/j.drugalcdep.2016.10.015.Treatment .
doi: 10.1016/j.drugalcdep.2016.10.015.Treatment
pubmed: 27810654
pmcid: 5223737